Functional Studies of Novel Genes Mutated in Primary Ciliary Dyskinesia II: Genotype to Phenotype

  • STATUS
    Recruiting
  • End date
    Apr 30, 2024
  • participants needed
    30
  • sponsor
    University of North Carolina, Chapel Hill
Updated on 24 March 2022

Summary

The purpose of this study is to measure mucociliary clearance (MCC) in groups of subjects with the disease Primary Ciliary Dyskinesia (PCD) caused by mutations in different genes. Some of these genes are associated with a milder clinical phenotype. This study seeks to determine if the milder phenotype is a result of mutations in a set of specific genes. The hypothesis is that subjects with PCD caused by mutations in the milder group will maintain a low, but significant rate of mucociliary clearance, while patients with mutations in genes in the more severe group will have a complete absence of mucociliary clearance. These studies will help inform future treatment strategies.

Description

Participants will undergo screening with basic physical exam and lung function testing at the start of the study. Participants will then inhale a radiolabeled substance and undergo medical imaging to measure the clearance of mucus in the airways. Albuterol will be administered after the first imaging is completed. Lung function testing will be repeated. Finally, medical imaging will be repeated two more times to further look at clearance of mucus in the lungs. The study will be completed in one day and will last about 6 hours.

Details
Condition Primary Ciliary Dyskinesia
Treatment Albuterol, Technetium99m - Sulfur Colloid (Tc99m-SC)
Clinical Study IdentifierNCT04901715
SponsorUniversity of North Carolina, Chapel Hill
Last Modified on24 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Confirmed PCD diagnosis with identified genetic mutations
Negative pregnancy test for females who are not s/p hysterectomy with oophorectomy
Forced Expiratory Volume (FEV1) of at least 30 percent of predicted

Exclusion Criteria

Any chronic medical condition considered by the PI as a contraindication to the exposure study including significant cardiovascular disease, diabetes, chronic renal disease, chronic thyroid disease, immunodeficiency, history of tuberculosis
Any acute infection requiring antibiotics within 4 weeks of study
Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the participant's ability to comply with study requirements
Medications which may impact the results of the study treatment, or may interfere with any other medications potentially used in the study (to include steroids, beta antagonists, non-steroidal anti-inflammatory agents)
Active smoking to include e-cigarettes within 1 year of the study, or lifetime of > 10 pack years of smoking
History of vaping or current vaping
Allergy/sensitivity to study drugs, or their formulations
Viral upper respiratory tract infection within 4 weeks of challenge
Radiation exposure history in the past year which would be outside the safe levels
Pregnant or lactating women will also be excluded since the risks associated with radiation are unknown and cannot be justified
Use of the following medications
Use of beta blocking medications
Receipt of LAIV (Live Attenuated Influenza Vaccine), also known as FluMist , within the prior 30 days, or any vaccine within the prior 5 days
Multivitamins, Vitamin C or E or herbal medications in the 4 days prior to the treatment visit
Non-steroidal anti-inflammatory drugs in the 4 days prior to the treatment visit
Allergy/sensitivity to study drugs or their formulations
Known Immunoglobulin E (IgE) mediated hypersensitivity to albuterol
Physical/laboratory indications
Temperature > 37.8 degrees Celsius (C)
Subjects >15 years- Systolic BP >150 mm hg or < 90 mm Hg or diastolic BP> 90 mm Hg or < 50 and Subjects 12-15 years - Systolic BP > 130 mmHg or < 80 mmHg or diastolic BP > 80 or <40
Oxygen saturation of < 93 percent
Inability or unwillingness of a participant to give written informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note